Zacks Investment Research downgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a report released on Wednesday, January 3rd.

According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “

LMAT has been the subject of a number of other research reports. Canaccord Genuity reiterated a hold rating and set a $30.00 price objective on shares of LeMaitre Vascular in a research report on Monday, October 9th. BidaskClub cut LeMaitre Vascular from a sell rating to a strong sell rating in a research report on Wednesday, December 27th. First Analysis cut LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 price objective for the company. in a research report on Friday, October 27th. Benchmark lowered LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday, October 27th. Finally, Stifel Nicolaus reissued a buy rating on shares of LeMaitre Vascular in a research note on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. LeMaitre Vascular has an average rating of Hold and a consensus price target of $32.20.

Shares of LeMaitre Vascular (NASDAQ LMAT) traded up $0.27 during mid-day trading on Wednesday, hitting $35.30. The stock had a trading volume of 82,351 shares, compared to its average volume of 114,583. LeMaitre Vascular has a twelve month low of $19.82 and a twelve month high of $39.88. The stock has a market capitalization of $674.85, a PE ratio of 45.84, a P/E/G ratio of 2.69 and a beta of 0.54.

In other news, insider David B. Roberts sold 4,123 shares of LeMaitre Vascular stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $32.14, for a total value of $132,513.22. Following the transaction, the insider now directly owns 24,482 shares of the company’s stock, valued at approximately $786,851.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 23.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. BB&T Corp purchased a new stake in LeMaitre Vascular during the 4th quarter worth approximately $202,000. Assenagon Asset Management S.A. purchased a new stake in LeMaitre Vascular during the 4th quarter worth approximately $1,184,000. Strs Ohio increased its holdings in LeMaitre Vascular by 16.6% during the 4th quarter. Strs Ohio now owns 22,500 shares of the medical instruments supplier’s stock worth $716,000 after purchasing an additional 3,200 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in shares of LeMaitre Vascular by 55.3% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,327,376 shares of the medical instruments supplier’s stock valued at $42,264,000 after acquiring an additional 472,732 shares during the last quarter. Finally, Thomson Horstmann & Bryant Inc. increased its holdings in shares of LeMaitre Vascular by 10.6% in the 4th quarter. Thomson Horstmann & Bryant Inc. now owns 356,517 shares of the medical instruments supplier’s stock valued at $11,351,000 after acquiring an additional 34,162 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Marea Informative and is owned by of Marea Informative. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.mareainformativa.com/2018/01/29/lemaitre-vascular-lmat-downgraded-by-zacks-investment-research-to-hold-updated-updated-updated.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.